Hormone therapy and phytoestrogens alleviate psychological symptoms in menopausal women, particularly mood and anxiety.
This systematic review and meta-analysis of 51 RCTs (n=41,821) for hormone therapy and 16 RCTs (n=1,191) for phytoestrogens found that both interventions reduced psychological symptoms in menopausal women, especially mood and anxiety. Tibolone showed a significant improvement in depression (SMD 0.93, 95% CI 0.62-1.24). Post-menopausal women experienced greater benefits for sleep quality with hormone therapy and for depression and anxiety with phytoestrogens compared to perimenopausal women.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Hormone therapy and phytoestrogens alleviate psychological symptoms in menopausal women, particularly mood and anxiety. The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).
The Claim
Hormone therapy and phytoestrogens alleviate psychological symptoms in menopausal women, particularly mood and anxiety.
This conclusion is most relevant to: Menopausal women (perimenopausal and post-menopausal).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy of hormone therapy and phytoestrogens on the psychological symptoms of menopausal women: a systematic review, meta-analysis, and trial sequential analysis. (Frontiers in medicine, 2026) — This systematic review and meta-analysis of 51 RCTs (n=41,821) for hormone therapy and 16 RCTs (n=1,191) for phytoestrogens found that both interventions reduced psychological symptoms in menopausal women, especially mood and anxiety. Tibolone showed a significant improvement in depression (SMD 0.93, 95% CI 0.62-1.24). Post-menopausal women experienced greater benefits for sleep quality with hormone therapy and for depression and anxiety with phytoestrogens compared to perimenopausal women.
How It Works
The proposed biological pathway:
- ▸Hormone therapy and phytoestrogens modulate estrogenic activity in the brain
- ▸Estrogen influences neurotransmitter systems involved in mood regulation
- ▸Reduction in vasomotor symptoms may indirectly improve sleep and psychological well-being
- ▸Result: Alleviation of psychological symptoms in menopausal women
Who Might Benefit
Evidence fit by population:
- ▸Menopausal women (perimenopausal and post-menopausal)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Some significant outcomes failed correction in trial sequential analysis and require further validation
- ▸Effects differed by symptom type and menopausal stage, limiting generalizability across all subgroups
Frequently Asked Questions
What psychological symptoms were improved by hormone therapy and phytoestrogens?▼
The study found improvements in mood, anxiety, depression, and sleep quality, with post-menopausal women showing greater benefits for sleep quality with hormone therapy and for depression and anxiety with phytoestrogens.
How large was the effect of Tibolone on depression?▼
Tibolone showed a significant improvement in depression with a standardized mean difference (SMD) of 0.93 and a 95% confidence interval of 0.62 to 1.24.
Were the findings statistically robust?▼
Trial sequential analysis confirmed the robustness of most findings, but some significant outcomes failed correction and require further validation.
Did the effects differ between perimenopausal and post-menopausal women?▼
Yes, post-menopausal women showed a greater beneficial effect of hormone therapy on sleep quality and of phytoestrogens on depression and anxiety compared to perimenopausal women.
References
- 1.Shou M, Ye M, Lou C, Chen X, Yao Y, Yan J, Zhou W, Fu Z, Liu Z. “Efficacy of hormone therapy and phytoestrogens on the psychological symptoms of menopausal women: a systematic review, meta-analysis, and trial sequential analysis..” Frontiers in medicine, 2026. PMID: 42500528 DOI: 10.3389/fmed.2026.1855845